tiprankstipranks
Advertisement
Advertisement

CBIO Stock Latest News

BTIG says others may be interested in Apogee Therapeutics
The FlyBTIG says others may be interested in Apogee Therapeutics
7d ago
JNJ
NVS
Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts
PremiumWeekend Updates
Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts
23d ago
CPB
SHW
Crescent Biopharma shareholders back directors, pay and auditor
PremiumCompany Announcements
Crescent Biopharma shareholders back directors, pay and auditor
25d ago
8K
CBIO
Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright
28d ago
CBIO
Crescent Biopharma reports Q1 EPS (70c), consensus (79c)
PremiumThe Fly
Crescent Biopharma reports Q1 EPS (70c), consensus (79c)
2M ago
CBIO
Crescent Biopharma management to meet with Cantor Fitzgerald
PremiumThe FlyCrescent Biopharma management to meet with Cantor Fitzgerald
3M ago
CBIO
Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright
Premium
The Fly
Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright
4M ago
CBIO
Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year
Premium
The Fly
Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year
4M ago
CBIO
Crescent Biopharma sees cash runway into 2028
PremiumThe Fly
Crescent Biopharma sees cash runway into 2028
4M ago
CBIO
3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts
4M ago
CBIO
CHWY
Crescent Biopharma announces grants of inducement awards
PremiumThe Fly
Crescent Biopharma announces grants of inducement awards
4M ago
CBIO
Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target
PremiumRatings
Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target
4M ago
CBIO
Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
PremiumThe FlyCrescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
4M ago
CBIO
Crescent Biopharma initiated with an Overweight at Piper Sandler
Premium
The Fly
Crescent Biopharma initiated with an Overweight at Piper Sandler
5M ago
CBIO
Crescent Biopharma initiated with a Buy at Guggenheim
Premium
The Fly
Crescent Biopharma initiated with a Buy at Guggenheim
5M ago
CBIO
SMMT
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage
PremiumCompany Announcements
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage
6M ago
CBIO
Crescent Biopharma files to sell 19.71M shares of common stock for holders
PremiumThe Fly
Crescent Biopharma files to sell 19.71M shares of common stock for holders
6M ago
CBIO
Crescent Biopharma: Advancing De-Risked Immuno-Oncology Pipeline and Strategic Partnerships Underscore Undervalued Buy Opportunity
PremiumRatings
Crescent Biopharma: Advancing De-Risked Immuno-Oncology Pipeline and Strategic Partnerships Underscore Undervalued Buy Opportunity
6M ago
CBIO
Crescent Biopharma announces regulatory clearance of IND applications
PremiumThe Fly
Crescent Biopharma announces regulatory clearance of IND applications
6M ago
CBIO
Two new option listings and eighteen option delistings on December 22nd
PremiumThe FlyTwo new option listings and eighteen option delistings on December 22nd
6M ago
QD
EPS
Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating
Premium
Ratings
Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating
7M ago
CBIO
Crescent Biopharma price target raised to $32 from $28 at Stifel
Premium
The Fly
Crescent Biopharma price target raised to $32 from $28 at Stifel
7M ago
CBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >